At the University of Colorado Anschutz Medical Campus, endocrinologist Dr
Viking Therapeutics, for instance, is developing VK2735, a dual GLP-1/GIP agonist that aims to achieve greater weight loss through the synergistic effects of dual agonism
The algorithm was designed to predict differences in one-year glycemic outcomes [based on glycated hemoglobin (HbA1c)] between the two therapies, using routine clinical features from 46,394 people with type 2 diabetes in England (27,319 for developing the model and 19,075 for validation, respectively), with additional external validation from 2,252 T2D patients in Scotland
Think about the patient taking multiple medications at multiple times in the day, or consider the patient taking a medication on an empty stomach It can be difficult for people to adjust their routine to fit the instruction
Researchers should maintain detailed logs documenting injection timing, dosage amounts, injection sites, and any observed effects or reactions
Ambrish Mithal weighs in on who should take it, how it works, and why it's not a shortcut to health